Inmed Pharmaceuticals Inc SEC Filings

Private investment funds managed by ADAR1 Capital Management, LLC bought 468,551 InMed Pharmaceuticals common shares in open-market transactions on May 19, 2026. Individual trades included 200,000 shares at $1.4990, 200,000 shares at $1.5604, and 68,551 shares at $1.5998, all reported as indirect ownership. Footnotes state the securities are owned directly by ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, who each disclaim beneficial ownership beyond their pecuniary interest.

InMed Pharmaceuticals Inc. filed an initial ownership report showing that private investment funds managed by ADAR1 Capital Management, LLC hold 331,449 Common Shares of InMed. These shares may be deemed indirectly beneficially owned by ADAR1 and by Daniel Schneeberger, its sole manager, through their interests in the funds.

Both ADAR1 and Schneeberger are listed as ten percent owners. The filing states that each reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

InMed Pharmaceuticals Inc. entered into an Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. to combine the companies through a two-step merger structure, subject to customary closing conditions and shareholder approvals. The Exchange Ratio is based on a contemplated Mentari equity value of $125,000,000 and related financing.

The parties expect, on a pro forma basis, pre-Merger Mentari stockholders to own approximately 98.49% and pre-Merger InMed shareholders approximately 1.51% of the combined company. Closing requires receipt of not less than $150,000,000 in Mentari's pre-closing financing, Nasdaq listing approval, the Form S-4 becoming effective, and shareholder approvals. The transaction contemplates issuance of non-voting Convertible Preferred Shares convertible into 1,000 Common Shares each and includes a Contingent Value Rights plan for pre-Merger InMed shareholders.

InMed Pharmaceuticals Inc. entered into an Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. to combine the companies through a two-step merger structure, subject to customary closing conditions and shareholder approvals. The Exchange Ratio is based on a contemplated Mentari equity value of $125,000,000 and related financing.

The parties expect, on a pro forma basis, pre-Merger Mentari stockholders to own approximately 98.49% and pre-Merger InMed shareholders approximately 1.51% of the combined company. Closing requires receipt of not less than $150,000,000 in Mentari's pre-closing financing, Nasdaq listing approval, the Form S-4 becoming effective, and shareholder approvals. The transaction contemplates issuance of non-voting Convertible Preferred Shares convertible into 1,000 Common Shares each and includes a Contingent Value Rights plan for pre-Merger InMed shareholders.

InMed Pharmaceuticals Inc. entered into an Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. to combine the companies through a two-step merger structure, subject to customary closing conditions and shareholder approvals. The Exchange Ratio is based on a contemplated Mentari equity value of $125,000,000 and related financing.

The parties expect, on a pro forma basis, pre-Merger Mentari stockholders to own approximately 98.49% and pre-Merger InMed shareholders approximately 1.51% of the combined company. Closing requires receipt of not less than $150,000,000 in Mentari's pre-closing financing, Nasdaq listing approval, the Form S-4 becoming effective, and shareholder approvals. The transaction contemplates issuance of non-voting Convertible Preferred Shares convertible into 1,000 Common Shares each and includes a Contingent Value Rights plan for pre-Merger InMed shareholders.

InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.

Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.

InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.

Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.

InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.

Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.

InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.

The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.

InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.

The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.

InMed Pharmaceuticals Inc. entered into an amending agreement with Armistice Capital Master Fund to change the terms of certain preferred investment options originally issued on October 26, 2023. These options give Armistice the right to purchase up to 278,761 common shares.

The exercise price for these preferred investment options is being reduced from $16.60 per share to $0.80 per share. The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and there is no assurance any of the options will be exercised.

InMed Pharmaceuticals reported third quarter fiscal 2026 results and a business update. The company is winding down BayMedica’s commercial operations, its only revenue-generating business segment, which is classified as discontinued operations and expected to be substantially exited before the fiscal year ending June 30, 2026.

For the three months ended March 31, 2026, InMed recorded a net loss of $3.0 million from total operations, compared with $2.1 million a year earlier, as research and development and general and administrative costs increased. Continuing operations generated no revenue, while discontinued commercial operations produced $0.7 million of revenue that is reported separately.

Cash, cash equivalents and short-term investments were $5.2 million as of March 31, 2026, down from $10.8 million on June 30, 2025. The company highlighted preclinical data for its CB1/CB2-targeting candidate INM-901, showing reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease, consistent with earlier in vivo and ex vivo findings.

InMed Pharmaceuticals Inc. has amended existing preferred investment options held by Sabby Volatility Warrant Master Fund and affiliates of H.C. Wainwright & Co. to significantly lower their exercise prices. Sabby’s options for up to 2,151,478 common shares were repriced from $2.436 to $0.80 per share.

Preferred investment options held by three Wainwright affiliates for up to 153,236 common shares, previously exercisable at $82.50, $20.75 and $3.2013 per share, were also repriced to $0.80. All of these options were originally issued in private placements under Section 4(a)(2) and Regulation D. The company later issued a press release describing these amendments.

InMed Pharmaceuticals Inc. filed a prospectus supplement and related prospectus on April 3, 2026 for the sale of its common shares under an existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. These potential sales are made pursuant to a shelf registration statement on Form S-3, which was filed on March 20, 2026 and declared effective on March 30, 2026.

The company also filed a legal opinion from Norton Rose Fulbright Canada LLP as Exhibit 5.1 covering the legality of the common shares issuable under the Sales Agreement and included a related consent as Exhibit 23.1.